Evidence map›Paper›PMID 42621935›Full record

ReviewFrontiers in immunology2026

OTULIN: a master regulator of linear ubiquitin homeostasis in immune signaling, inflammation, and disease.

Ziyu Zhang, Jiahang Lyu, Yujie Bai, Zhen Guo, Qifu Bo, Kai Liu, Xiangpeng Dai

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ziyu Zhang *First Hospital of Jilin University, Changchun, Jilin, China.
Jiahang Lyu *First Hospital of Jilin University, Changchun, Jilin, China.
Yujie BaiFirst Hospital of Jilin University, Changchun, Jilin, China.
Zhen GuoFirst Hospital of Jilin University, Changchun, Jilin, China.
Qifu BoDepartment of Comprehensive Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Kai LiuFirst Hospital of Jilin University, Changchun, Jilin, China.
Xiangpeng DaiKey Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OTU deubiquitinase with linear linkage specificity (OTULIN) is the only deubiquitinase known to exhibit strict specificity for Met1-linked linear ubiquitin chains, serving as a critical regulator that restrains linear ubiquitin chain assembly complex and maintains inflammatory homeostasis and tissue integrity. Advances over recent years have reshaped our understanding of OTULIN from a negative regulator confined to the canonical nuclear factor kappa-light-chain-enhancer of activated B cells pathway to a central editor governing linear ubiquitin network homeostasis. Its functional repertoire spans receptor-proximal inflammatory signaling, cell death fate determination, inflammasome activation, autophagy, and cellular stress adaptation. Emerging evidence from human genetics and animal models has further broadened the OTULIN-associated disease spectrum, revealing that pathogenesis arises from imbalanced linear ubiquitin networks coupled with cell type and tissue context dependent inflammatory dysregulation. Here, we provide a comprehensive overview of OTULIN's structural features, regulatory mechanisms, biological functions, roles in pathogenesis, and potential therapeutic intervention strategies, aiming to inform future mechanistic studies and facilitate translational advances in targeted therapies.

Indexed as

EndopeptidasesHomeostasisInflammationSignal TransductionUbiquitinAnimalsDeubiquitinating EnzymesHumansUbiquitinationDeubiquitinating EnzymesEndopeptidasesOTULIN protein, humanUbiquitinimmune homeostasislinear ubiquitinationLUBACNF-κBOTULINtargeted therapy

Identifiers

PMID42621935
PMCPMC13487742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.